Cocrystal Pharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COCP research report →
Companywww.cocrystalpharma.com
Cocrystal Pharma, Inc. , a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.
- CEO
- Sam Lee
- IPO
- 2012
- Employees
- 11
- HQ
- Bothell, WA, US
Price Chart
Valuation
- Market Cap
- $11.38M
- P/E
- -1.73
- P/S
- 50.56
- P/B
- 3.72
- EV/EBITDA
- -0.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 669.78%
- Op Margin
- -4015.11%
- Net Margin
- -3924.00%
- ROE
- -150.61%
- ROIC
- -163.07%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-8,831,000 · 49.55%
- EPS
- $-0.78 · 54.65%
- Op Income
- $-9,019,000
- FCF YoY
- 50.26%
Performance & Tape
- 52W High
- $2.67
- 52W Low
- $0.86
- 50D MA
- $1.28
- 200D MA
- $1.19
- Beta
- 1.50
- Avg Volume
- 2.48M
Get TickerSpark's AI analysis on COCP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 24, 26 | FROST PHILLIP MD ET AL | buy | 20,000 |
| Feb 6, 26 | FROST PHILLIP MD ET AL | buy | 50,000 |
| Jan 9, 26 | Kornberg Roger D. | other | 24,615 |
| Jan 9, 26 | PFENNIGER RICHARD C JR | other | 16,410 |
| Jan 9, 26 | Lee Sam | other | 49,229 |
| Jan 9, 26 | Hassan Fred | other | 16,410 |
| Jan 9, 26 | Martin James Joseph | other | 49,229 |
| Jan 9, 26 | FROST PHILLIP MD ET AL | other | 24,615 |
| Jan 9, 26 | Japour Anthony J | other | 16,410 |
| Jan 9, 26 | Rubin Steven D | other | 16,410 |
Our COCP Coverage
We haven't published any research on COCP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate COCP Report →